On June 22, 2026 Can-Fite BioPharma Ltd. (NYSE American: CANF) (TASE: CANF), a biotechnology company advancing a pipeline of proprietary small molecule drugs that address oncological and inflammatory diseases, reported the publication of a peer-reviewed scientific article demonstrating the broad therapeutic potential of its lead drug candidates, Piclidenoson and Namodenoson, across multiple major diseases.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
"The article, entitled "Adenosine A3 Receptor Agonists as Multisystemic Disease Modifiers: From Molecular Signaling to Clinical Translation" was published in the peer-reviewed Biomolecules Journal (link). The publication reviews findings from Can-Fite work and numerous independent academic and clinical research groups worldwide demonstrating that activation of the A3 adenosine receptor (A3AR) modulates key pathological pathways involved
The review details evidence supporting A3AR agonist activity in:
● Solid tumors, including hepatocellular carcinoma and pancreatic cancer
● Metabolic dysfunction-associated steatohepatitis (MASH) and liver fibrosis
● Autoimmune and inflammatory diseases
● Osteoarthritis and musculoskeletal disorders
● Neurodegenerative diseases, including Alzheimer’s disease and vascular dementia
● Obesity and metabolic disorders
● Rare genetic diseases, including Lowe syndrome
"This publication represents an important scientific validation of Piclidenoson and Namodenoson and the broader A3AR platform technology," stated Pnina Fishman, CSO and Chairperson of Can-Fite. "Particularly compelling is the fact that many of the findings summarized in this review originate from independent research institutions worldwide and extend well beyond our current clinical development programs. Collectively, we believe these data reinforce the potential of A3AR agonists to address multiple diseases with significant unmet medical needs."
Can-Fite’s clinical pipeline currently includes Namodenoson in Phase 3 development for hepatocellular carcinoma, Phase 2 development for pancreatic cancer, and Phase 2b development for MASH. Piclidenoson is currently being evaluated in a pivotal Phase 3 study in psoriasis. The publication further supports the Company’s strategy of leveraging A3AR agonists as a platform technology applicable to multiple therapeutic indications.
(Press release, Can-Fite BioPharma, JUN 22, 2026, View Source [SID1234668852])